View ValuationCellid 将来の成長Future 基準チェック /06現在、 Cellidの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長37.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 07Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South KoreaNew Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩101.2b market cap, or US$70.7m).お知らせ • Jun 18Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 4260 Discount Per Security: KRW 76.68 Transaction Features: Rights OfferingNew Risk • May 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩84.0b market cap, or US$60.0m).New Risk • Apr 23New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩78.5b market cap, or US$55.1m).お知らせ • Mar 19Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion.Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 2875 Transaction Features: Rights Offeringお知らせ • Feb 27Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea分析記事 • Dec 10Is Cellid (KOSDAQ:299660) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩2.3b revenue, or US$1.6m). Market cap is less than US$100m (₩120.1b market cap, or US$86.1m).New Risk • Aug 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (₩914m revenue, or US$684k).お知らせ • Aug 08Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,422,072 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,077,928 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Transaction Features: Rights OfferingNew Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$22.4m).New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩39.4b market cap, or US$29.0m).分析記事 • Feb 28Is Cellid (KOSDAQ:299660) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Sep 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$356k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩57.6b market cap, or US$42.8m).New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$373k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$49.9m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 21Cellid, Co., Ltd. announced that it has received KRW 19 billion in fundingOn March 19, 2021, Cellid, Co., Ltd. (KOSDAQ:A299660) closed the transaction.お知らせ • Mar 19Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in fundingCellid, Co., Ltd. (KOSDAQ:A299660) announced a private placement of 2nd series unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 19,000,000,000 on March 17, 2021. The transaction will include participation from Daily Bio Health Care 1 Startup Venture Private Equity Joint Venture. The bonds will carry a zero coupon rate and zero yield to maturity. The bonds will mature on March 19, 2026. The bonds will be fully convertible into 515,296 shares of the company at a price of KRW 36,872 per share between the period of March 19, 2022 to February 19, 2026. The transaction has been approved by the board of directors of the company. The expected payment date and subscription date is March 19, 2021.分析記事 • Mar 04Is Cellid (KOSDAQ:299660) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Feb 25Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 13New 90-day low: ₩37,650The company is down 24% from its price of ₩49,250 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period.分析記事 • Nov 19Cellid (KOSDAQ:299660) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is New 90 Day High Low • Oct 05New 90-day high: ₩50,700The company is up 81% from its price of ₩28,050 on 07 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cellid は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A299660 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: A299660の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A299660の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A299660の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A299660の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A299660の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A299660の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:54終値2026/05/22 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cellid, Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 07Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩101.2b market cap, or US$70.7m).
お知らせ • Jun 18Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 4260 Discount Per Security: KRW 76.68 Transaction Features: Rights Offering
New Risk • May 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩84.0b market cap, or US$60.0m).
New Risk • Apr 23New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩78.5b market cap, or US$55.1m).
お知らせ • Mar 19Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion.Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 2875 Transaction Features: Rights Offering
お知らせ • Feb 27Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea
分析記事 • Dec 10Is Cellid (KOSDAQ:299660) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩2.3b revenue, or US$1.6m). Market cap is less than US$100m (₩120.1b market cap, or US$86.1m).
New Risk • Aug 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (₩914m revenue, or US$684k).
お知らせ • Aug 08Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,422,072 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,077,928 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Transaction Features: Rights Offering
New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$22.4m).
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩39.4b market cap, or US$29.0m).
分析記事 • Feb 28Is Cellid (KOSDAQ:299660) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Sep 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$356k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩57.6b market cap, or US$42.8m).
New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$373k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$49.9m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 21Cellid, Co., Ltd. announced that it has received KRW 19 billion in fundingOn March 19, 2021, Cellid, Co., Ltd. (KOSDAQ:A299660) closed the transaction.
お知らせ • Mar 19Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in fundingCellid, Co., Ltd. (KOSDAQ:A299660) announced a private placement of 2nd series unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 19,000,000,000 on March 17, 2021. The transaction will include participation from Daily Bio Health Care 1 Startup Venture Private Equity Joint Venture. The bonds will carry a zero coupon rate and zero yield to maturity. The bonds will mature on March 19, 2026. The bonds will be fully convertible into 515,296 shares of the company at a price of KRW 36,872 per share between the period of March 19, 2022 to February 19, 2026. The transaction has been approved by the board of directors of the company. The expected payment date and subscription date is March 19, 2021.
分析記事 • Mar 04Is Cellid (KOSDAQ:299660) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Feb 25Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 13New 90-day low: ₩37,650The company is down 24% from its price of ₩49,250 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period.
分析記事 • Nov 19Cellid (KOSDAQ:299660) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Is New 90 Day High Low • Oct 05New 90-day high: ₩50,700The company is up 81% from its price of ₩28,050 on 07 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period.